World Asset Management Inc lowered its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.7% during the second quarter, Holdings Channel reports. The firm owned 21,130 shares of the biopharmaceutical company’s stock after selling 3,067 shares during the period. World Asset Management Inc’s holdings in Alexion Pharmaceuticals were worth $2,571,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in the stock. Daiwa Securities Group Inc. raised its stake in shares of Alexion Pharmaceuticals by 3.3% in the second quarter. Daiwa Securities Group Inc. now owns 6,300 shares of the biopharmaceutical company’s stock worth $767,000 after buying an additional 200 shares during the period. Edge Wealth Management LLC bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth about $1,581,000. Grove Bank & Trust raised its stake in shares of Alexion Pharmaceuticals by 194.7% in the second quarter. Grove Bank & Trust now owns 1,347 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 890 shares during the period. Bessemer Group Inc. raised its stake in shares of Alexion Pharmaceuticals by 1,949,640.5% in the second quarter. Bessemer Group Inc. now owns 721,404 shares of the biopharmaceutical company’s stock worth $87,772,000 after buying an additional 721,367 shares during the period. Finally, Lockheed Martin Investment Management Co. raised its stake in shares of Alexion Pharmaceuticals by 68.6% in the second quarter. Lockheed Martin Investment Management Co. now owns 17,200 shares of the biopharmaceutical company’s stock worth $2,093,000 after buying an additional 7,000 shares during the period. 94.84% of the stock is owned by institutional investors and hedge funds.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 137.99 on Friday. The stock’s 50 day moving average price is $123.43 and its 200 day moving average price is $122.81. The company has a market capitalization of $30.91 billion, a P/E ratio of 59.84 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $145.42.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the prior year, the company posted $1.13 EPS. The company’s quarterly revenue was up 21.1% on a year-over-year basis. On average, equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.41 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://stocknewstimes.com/2017/07/30/alexion-pharmaceuticals-inc-alxn-shares-sold-by-world-asset-management-inc.html.
A number of brokerages have issued reports on ALXN. BMO Capital Markets increased their price objective on shares of Alexion Pharmaceuticals from $159.00 to $168.00 and gave the company an “outperform” rating in a report on Friday. Leerink Swann increased their price objective on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a report on Friday. Oppenheimer Holdings, Inc. raised shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price objective for the company in a report on Friday. Morgan Stanley reaffirmed an “overweight” rating and set a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday. Finally, BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Six investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $156.85.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the purchase, the chief executive officer now directly owns 38,725 shares in the company, valued at approximately $4,519,982. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 2,019,734 shares of company stock worth $235,606,846. Corporate insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
